Literature DB >> 1625189

Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.

C A Paronis1, S G Holtzman.   

Abstract

We investigated the role of intrinsic activity in the ability of mu-opioid agonists to produce tolerance to the analgesic effects of other mu agonists. Dose-response curves were generated for each test drug before and 24 hr after 1 week s.c. agonist infusions, using a tail-flick procedure in male rats. Morphine tolerance was dose-dependent over a range of doses, 0.3 to 1.4 mg/kg/hr, infused for 7 days by osmotic pump; 0.8 mg/kg/hr (1/4 acute ED50/hr) shifted the morphine dose-response curve roughly 2-fold to the right. Morphine, fentanyl or meperidine were then infused for 1 week to induce tolerance; doses were based on equipotent acute s.c. doses (1/4 ED50/hr). Drugs tested for analgesic activity, using a cumulative dosing procedure, included morphine, fentanyl, meperidine, methadone, buprenorphine, etorphine and levorphanol. The relative potency (RP) was calculated for each animal by dividing the preinfusion analgesic ED50 by the postinfusion ED50. The potency of morphine, fentanyl, meperidine and levorphanol decreased after a 7-day infusion of 0.8 mg/kg/hr morphine (RP = 0.44-0.70), but the potency of etorphine (RP = 0.85) and methadone (RP = 0.78) were not significantly changed. Chronic infusions of 6.25 mg/kg/hr meperidine produced more tolerance than did morphine (RP = 0.11-0.51). No significant change in analgesic potency was seen in six of the seven test drugs after infusions of 0.01 mg/kg/hr fentanyl (RP = 0.81-1.27). Buprenorphine did not produce an analgesic response in rats that received infusions of any of the three mu agonists. The RP of drugs with low intrinsic activity was lower than the RP of high efficacy drugs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1625189

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

2.  Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Authors:  Carol A Paronis; Girish R Chopda; Kiran Vemuri; Ani S Zakarian; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2018-01-08       Impact factor: 4.030

3.  Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.

Authors:  David R Maguire; Charles P France
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

4.  Increased sensitivity to Salmonella enterica serovar Typhimurium infection in mice undergoing withdrawal from morphine is associated with suppression of interleukin-12.

Authors:  Pu Feng; Qiana M Wilson; Joseph J Meissler; Martin W Adler; Toby K Eisenstein
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine.

Authors:  E A Walker; T M Richardson; A M Young
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

Review 6.  Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications.

Authors:  Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  IUBMB Life       Date:  2010-02       Impact factor: 3.885

7.  Morphine and fentanyl differently affect MOP and NOP gene expression in human neuroblastoma SH-SY5Y cells.

Authors:  Francesca Felicia Caputi; Francesca Lattanzio; Donatella Carretta; Daniela Mercatelli; Sanzio Candeletti; Patrizia Romualdi
Journal:  J Mol Neurosci       Date:  2013-05-29       Impact factor: 3.444

8.  Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.

Authors:  Carol A Paronis; Spyros P Nikas; Vidyanand G Shukla; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

9.  Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment.

Authors:  F Noble; B M Cox
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

10.  Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

Authors:  Priyank Kumar; Soujanya Sunkaraneni; Sunil Sirohi; Shveta V Dighe; Ellen A Walker; Byron C Yoburn
Journal:  Eur J Pharmacol       Date:  2008-08-30       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.